Business Wire

L&T-TECHNOLOGY

15.3.2024 04:16:26 CET | Business Wire | Press release

Share
L&T Technology Services (LTTS) Secures Landmark ∼$100 Million Program in Cybersecurity

L&T Technology Services Limited (LTTS) (BSE: 540115, NSE: LTTS), a leading global pure-play engineering and technology services company, announced today that it has won a first-of-its-kind program in India worth around $100 million from Maharashtra State Cyber Department, under the Government of Maharashtra. This initiative extends LTTS’ commitment to developing secure, digitally interconnected smart and safe cities through premier Cyber Security and Digital Forensic solutions consolidated under one umbrella.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314467779/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

First-of-its-kind program in India entails designing a sophisticated cybersecurity system using AI & Digital Forensic tools. (Photo: Business Wire)

In this pioneering initiative by the Government of Maharashtra, LTTS in consortium with M/s KPMG Assurance and Consulting Services LLP as forensics partner will provide advanced Cyber Security Solutions for the State enhancing public safety against cyber threats.

The project entails designing a sophisticated cybersecurity system and establishing a state-of-the-art, fully equipped, Cyber security and Cybercrime prevention Centre to address Cybercrime Incidents and Investigations by leveraging AI and Digital Forensic tools. The program also encompasses the following:

  • A Digital Threat Analytics Centre (DTAC) paired with a Centre of Excellence (COE) that will equip the forensic team with cutting edge digital forensic tools including Deepfake detection, Mobile Malware forensics, IoT investigation, Network forensics, object detection supporting crypto & blockchain, Hardware & Embedded forensics, drone forensics, social media forensics, image enhancement, voice analysis labs, IMEI/CDR analysis, CCTV acquisition tools and computer forensics to streamline crime scene management, reduce timelines and improve the efficiency of cybercrime investigations.
  • A Central Emergency Response Team (CERT) to deal with incident response and investigation based on advanced cyber threat intelligence and analytics like APT detection and data breach, adversary intelligence from darknet, advanced malware analysis, proactive threat hunting and red teaming.
  • State-of-the-art Security Operations Centre (SOC) fortified by AI & ML technologies with a skilled cyber team to protect critical infrastructure. SOC handles Endpoint Detection & Response, SIEM, SOAR, UEBA, ZTNA, CASB, DLP, NAC, DNS Security, IDAM, and PAM solutions.

The integration of Smart World and Communication within LTTS has significantly amplified its capabilities, enabling the company to provide advanced engineering solutions for public cyber safety leveraging experience of setting up 25+ command centers. The successful execution of this project in India will pave the way for LTTS to extend these capabilities globally.

Commenting on the milestone win, Amit Chadha, CEO and Managing Director of L&T Technology Services, said, "This first-of-its-kind deal is more than just a business achievement for us. It’s an opportunity to leverage our experience in setting up over 25 command centers and recognizing the growing criticality of cybersecurity and the need to invest in advanced digital safeguard platforms and tools for the benefit of the larger society. This deal will set the stage for LTTS to scale its offerings for our global clientele.”

M/s KPMG Assurance and Consulting Services LLP., as LTTS' consortium partner, has played a critical role in this engagement. Yezdi Nagporewalla, Chief Executive Officer, KPMG in India, said, "We are truly proud to be part of this groundbreaking initiative. Collaborating with Maharashtra State Cyber Department and LTTS as a forensic services partner is a matter of pride for KPMG and it showcases our shared commitment to public safety by providing advanced cyber security solutions to counter cyber threats."

ABOUT L&T TECHNOLOGY SERVICES

L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,200 employees spread across 22 global design centers, 28 global sales offices and 105 innovation labs as of December 31, 2023. For more information, please visit https://www.LTTS.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240314467779/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye